Real world EGFR and ALK data: Malaysian Lung Cancer Registry
Dr Ernest Poh Mau Ern, University Malaya Medical Centre

Tyrosine kinase inhibitors (TKIs) have been shown to significantly prolong progression free survival in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement in various clinical trials. In recent years, there has been a keen interest looking at evaluation of these drugs in the real world setting across various different countries, both in the West and the East. Such data allows us a closer look at prevalence and risk factors, testing rates and methods, accessibility to these drugs in the local setting, treatment patterns, and outcomes such as survivability of patients outside of a randomized controlled setting. Here, we present some preliminary data from our local registry which gives some insight to the above.